Molecular Diagnostics Collaboration and Licensing Deals 2016-2023

$3,995.00

Molecular Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
November 2023
Number of pages
400+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP2102mol

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 673 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse molecular diagnostics collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:
•    Trends in molecular diagnostics dealmaking in the biopharma industry
•    Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
•    The leading molecular diagnostics deals by value
•    Most active molecular diagnostics licensing dealmakers

Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse molecular diagnostics collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in molecular diagnostics dealmaking
2.1. Introduction
2.2. Molecular diagnostics deals over the years
2.3. Most active molecular diagnostics dealmakers
2.4. Molecular diagnostics deals by deal type
2.5. Molecular diagnostics deals by therapy area
2.6. Molecular diagnostics deals by industry sector
2.7. Deal terms for molecular diagnostics deals
2.7.1 Molecular diagnostics deals headline values
2.7.2 Molecular diagnostics deal upfront payments
2.7.3 Molecular diagnostics deal milestone payments
2.7.4 Molecular diagnostics royalty rates

Chapter 3 – Leading molecular diagnostics deals
3.1. Introduction
3.2. Top molecular diagnostics deals by value

Chapter 4 – Most active molecular diagnostics dealmakers
4.1. Introduction
4.2. Most active molecular diagnostics dealmakers
4.3. Most active molecular diagnostics deals company profiles

Chapter 5 – Molecular diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 – Molecular diagnostics dealmaking by technology type

Deal directory

Deal directory – Molecular diagnostics deals by company A-Z
Deal directory – Molecular diagnostics deals by deal type
Deal directory – Molecular diagnostics deals by therapy area

Deal type definitions

About Wildwood Ventures    
Current Partnering
Current Agreements
Recent report titles from Current Partnering



Table of figures

Figure 1: Molecular diagnostics deals since 2016
Figure 2: Active molecular diagnostics dealmaking activity – 2016 - 2023
Figure 3: Molecular diagnostics deals by deal type since 2016
Figure 4: Molecular diagnostics deals by therapy area since 2016
Figure 5: Molecular diagnostics deals by industry sector since 2016
Figure 6: Molecular diagnostics deals with a headline value
Figure 7: Molecular diagnostics deals with an upfront value
Figure 8: Molecular diagnostics deals with a milestone value
Figure 9: Molecular diagnostics deals with a royalty rate value
Figure 10: Top molecular diagnostics deals by value since 2016
Figure 11: Most active molecular diagnostics dealmakers 2016 - 2023
Figure 12: Molecular diagnostics deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2bPrecise, 2cureX, 4bases, 4D Path, 10X Genomics, 23andMe, 221b Foundation, Academic Breast Cancer Consortium, Accelerate Technologies, AccuGenomics, AccuStem Sciences, AchilleS Vaccines, Acumen Diagnostics, Adaptive Biotechnologies, Aditx Therapeutics, Admera Health, ADT Altona Diagnostic Technologies, Advanced Cell Diagnostics, Aegea Biotechnologies, Age Labs, Agena Bioscience, Agilent Technologies, Agios Pharmaceuticals, Akonni Biosystems, Akoya Biosciences, Alamar Biosciences, Albertsons Companies, ALBOT Technologies, Aldeyra Therapeutics, Allelica, Almac Diagnostics, Alnylam Pharmaceuticals, Alveo Technologies, Alzheimer's Drug Discovery Foundation, Alzheon, Amazon Web Services, Ambry Genetics, Amgen, Amoy Diagnostics, AnchorDx, Angle, Anixa Biosciences, Anpac Bio-Medical Science, AnteoTech, Antisoma Therapeutics, Aptamer Therapeutics, Aptorum Group, Arbor Biosciences, ArcherDX, Ares Genetics, Ares Life Sciences, Arisan Therapeutics, Arizona State University, Artidis, Asep Medical, Ashion Analytics, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, Asterand Bioscience, Asthma UK, AstraZeneca, Atlas Antibodies, Atrin Pharmaceuticals, Avacta, Avera Health, AXIM Biotechnologies, Babson Diagnostics, Baebies, Bay Area Lyme Foundation, Bayer, Baylor Scott and White Research Institute, BC Neuroimmunology, BC Platforms, Beckman Coulter, Becton Dickinson, Beijing Genomics Institute (BGI), Berg, Berkeley Lights, Beroni Group, Berry Genomics, Be The Match BioTherapies, BGN Technologies, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bio-Me, Bio-Rad Laboratories, Bio-Techne, bioAffinity Technologies, BIOASTER, Biocartis, Biocept, Biocodices, Biodesix, Biodirection, BioExcel Diagnostics, Biofidelity, Biogenar, Biognosys, BioGX, BioInvent, BioIQ, Biological Dynamics, BioMark Diagnostics, Biomedical Advanced Research and Development Authority, Biomeme, Biomerica, Biomillenia, Biosearch Technologies, BioSkryb, BioSure, BL&H, Blu Biotech, Blue Cross Blue Shield Association, Blueprint Genetics, Boehringer Ingelheim, Boreal Genomics, Bosch, BostonGene, Brahms, Brandeis University, Brazlex Medical Genetics, Breath Diagnostics, Bredis Healthcare, Brigham and Women's Hospital, BrightPath Biotherapeutics, Bristol-Myers Squibb, Broad Institute, Brotman-Baty Institute, Bruker, Burning Rock, BurstIQ, C2i Genomics, C2Sense, Calviri, Cambridge Enterprise, Cambridge Epigenetix, Canadian Cancer Society, Canadian Institutes of Health Research, Cancer Research Institute, Cantabio Pharmaceuticals, Capsulomics, CARB-X, Cardea Bio, Cardiff University, CareDx, CareFirst BlueCross BlueShield, Caris Life Sciences, Carpegen, Case Western Reserve University, Castle Biosciences, CeGaT, Celcuity, Celgene, Cell Guidance Systems, CellMax Life, Cell Microsystems, Cellpath, Celsius Therapeutics, Cenetron, Centers for Disease Control and Prevention, Centogene, Centre Leon Berard, Cepheid, Cerba HealthCare, Cerveau Technologies, Charcot-Marie-Tooth Association, Charles River Laboratories, Chembio Diagnostics, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Orange County, Christian Doppler Research Association, ChromaCode, Chronix Biomedical, Chubu University, Cicero Diagnostics, Cipla, Circulogene, City of Hope, Clarity Pharmaceuticals, Cleveland Clinic, Cleveland Diagnostics, Cleveland University Hospitals, CND Life Sciences, Co-Diagnostics, Codexis, Cofactor Genomics, Colorado Melanoma Foundation, Columbia University, Companion Medical, Concert Genetics, Congenica, Contextual Genomics, Cooper Companies, Copenhagen University Hospital, CoreBiome, Coriell Life Sciences, Cornell University, Corteva Agriscience, Covance, Cradle Genomics, CrisprBits, Criterium, CSI Laboratories, Cue Health, Culmination Bio, Cumming, Curetis, Curta, Cypre, Cytox, Daiichi Sankyo, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, DarioHealth, Dartmouth-Hitchcock Medical Center, DarwinHealth, DCN Diagnostics, Decipher Biosciences, deCODE Genetics, Deep Bio, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Definiens, Dell Medical School, Delphi Diagnostics, Denali Therapeutics, Dendreon, Denso, Department of Defense, Department of Health and Human Services, DermTech, DestiNA Genomics, Devyser Diagnostics, DiaCarta, DiamiR, DIAN Diagnostics, Diaprost, DiaSorin, Diatech Pharmacogenetics, Diesse Diagnostica Senese, DNAmito, DoMore Diagnostics, Domus Diagnostics, Drawbridge Health, Duchenne UK, Duke University, DxTerity, DxVx, DYNEX Technologies, E25Bio, EchelonDx, Edico Genome, EDP Biotech, Eisai, Elevation Oncology, Eli Lilly, Elucigene, Empowered Diagnostics, Enterome Bioscience, Enzyre, Enzyvant Science, Epic, EpicGenetics, Epicore Biosystems, Epic Sciences, Epiphany Dermatology, Epivax, ESSA Pharma, Ethos Laboratories, Ethos Research & Development, Ethos Veterinary Health, Euformatics, Eureka Eurostars, EuroClone, Eurofins Scientific, European Institute of Oncology (EIO), European Organization for Research and Treatment of Cancer, European Union, Evogen, Evotec, Exact Sciences, Exagen Diagnostics, Exai Bio, Exigent Research, Exosome Sciences, Expedeon, Expesicor, ExSeed, F-Star Therapeutics, Factorial Diagnostics, Falco, First Genetics JCS, Flagship Biosciences, Flatiron Health, FlowMetric, Fluxion Biosciences, FLX Bio, Fondation Cancer, Fondatioun Kriibskrank Kanner, Foundation Medicine, Fox Chase Cancer Center, Freenome, Friends of Cancer Research, Fudan University, Fujirebio Diagnostics, Fulgent Genetics, Fundacion Progreso y Salud, Fusion Genomics, FYR Diagnostics, Galectin Therapeutics, Gemini Therapeutics, Gencove, GeneCentric Therapeutics, GeneDX, GeneNews, Genentech, GeneThera, Genetic Alliance, Genetic Analysis, Genetic Technologies, Genfit, Genome Canada, GenomeDx, Genome Prairie, Genomic Health, Genomic Testing Cooperative, Genomill Health, Genomind, GenoScreen, Genosity, GenScript Biotech, German Federal Ministry of Education and Research, Gestalt Diagnostics, GI OnDEMAND, GNS Healthcare, Good Start Genetics, Government of Canada, Government of South Korea, Grail, Gritstone Bio, Group K Diagnostics, GSK, GSK Consumer Healthcare, Guardant Health, Hackensack Meridian Health, HALO Precision Diagnostics, Hamilton Robotics, Harbinger Health, Harvard University, HEALTH Biomed, Heat Biologics, Hebrew University of Jerusalem, Helio Health, Helix, Hemex Health, Henan Cancer Hospital, Hereditary Neuropathy Foundation, HiloProbe, HMicro, Hoag Memorial Hospital Presbyterian, Hologic, Horizon Discovery, Hospital Clinic of Barcelona, HTG Molecular Diagnostics, Hubrecht Organoid Technology, Hummingbird Bioscience, Hummingbird Diagnostics, Ibex Medical Analytics, Icahn School of Medicine at Mount Sinai, ICAN, Idaho Urologic Institute, IDbyDNA, Idengene, Ikonopedia, Illumina, ImageMover, ImaginAb, IMBdx, Imec, ImmunArray, Immunexpress, ImmunID Technologies, ImmunoPrecise Antibodies, Immunovia, Imperial College London, IncellDx, InDevR, Indica Labs, Indivumed, Infinity BiologiX, Inflammatix, Informed Data Systems, Inivata, Innoplexus, Innovate UK, Institut Català d'Oncologia, Institut Curie, Institute for Bioscience and Biotechnology Research, Institute for Genome Statistics and Bioinformatics, Institute of Cancer Research, Institute of Human Genetics, Institute of Organic Chemistry and Biochemistry, Institut Gustave Roussy, Institut Paoli-Calmettes, Institut Pasteur, Integrated Biobank of Luxembourg, Integrated Micro-Chromatography Systems, Intermountain Healthcare, International Isotopes, Interpace Diagnostics, Invitae, InVivoScribe, ION Solutions, IRX Therapeutics, IsoPlexis, ISOThrive, JADBio, Janssen-Cilag, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Agency for Medical Research and Development, Jefferson Healthcare, Jeffrey Modell Foundation, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wayne Cancer Institute, Juntendo University, Karolinska Institute, Karolinska University Hospital, KDx Diagnostics, KELTIC Pharma, Kephera Diagnostics, KEW, Kite Pharma, Knight Cancer Institute, Konica Minolta Precision Medicine, Krystal Biotech, Kura Oncology, Labcyte, Laboratory Corporation of America, La Jolla Institute for Allergy & Immunology, LamdaGen, Lantheus Holding, Latvian Institute of Organic Synthesis, Leap Therapeutics, Leica Biosystems, Leicester University, Leinco Technologies, LEO Pharma, Les Laboratoires Servier, LexaGene, Lexent Bio, LifeLabs Medical Laboratory Services, Life Raft Group, LifeX Ventures, Li Ka Shing Foundation, Little Warrior Foundation, Liverpool School of Tropical Medicine, LogicInk, Longhorn Vaccines and Diagnostics, Lorna Linda University, Loxo Oncology, Lucence, Lucid Diagnostics, Luminex, LuminUltra, LumiraDx, Lunit, Lupus Research Alliance, Magellan Healthcare, Magenta Therapeutics, Magnetrap, Mammoth Biosciences, Manhattan Scientifics, Mannin Research, Massachusetts General Hospital, Massachusetts Institute of Technology, Maxim Biomedical, Mayo Clinic, MBio Diagnostics, McMaster University, MD Anderson Cancer Center, MD Biosciences, MDNA Life Sciences, MDxHealth, MEDIAN Technologies, Medical University of Graz, Medical University of Vienna, MediSapiens, Medosome Biotec, MeMed, Memorial Sloan Kettering Cancer Center, Menon Biosensors, Merck and Co, Merck KGaA, Mesa Biotech, Metabiomics, Metabolomic Diagnostics, Metabolon, MGI Pharma, Michael J Fox Foundation, Michelson Center, Microbix Biosystems, Microsoft, Mie University, Mimetas, MIODx, miR Scientific, MiRXES, MiTest Health, Moderna, Molbio Diagnostics, Molecular Health, MolecularMD, Molecular Stethoscope, Molecular Targeting Technologies, MolGen, Mologic, Monoceros Biosystems, Montana State University, Moss Genomics, Mount Sinai Health System, mProbe Laboratories, MRIGlobal, MRM Proteomics, Multi G, Multiplex Genomics, Muscular Dystrophy Association, Myelopro Diagnostics and Research, Mylab Discovery Solutions, Myriad Genetics, NanoMab Technology, NanoSpot.ai, NanoString Technologies, NantHealth, Natera, National Cancer Center, National Cancer Center of Japan, National Cancer Centre Singapore, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institutes of Health, National Science Foundation, Natural Sciences and  Engineering Research Council of Canada, Naveris, NEC, Nektar Therapeutics, NeoDynamics, Neogap Therapeutics, Neogen, Neogenomics, NeuMoDx Molecular, Neuro Bio, NeuroSense Therapeutics, New England Biolabs, New Horizon Health, NewStem, Next Gen Diagnostics, Northwestern University, Norwegian Institute of Public Health, Norwegian Research Council, Notable Labs, Novartis, NovellusDx, Novogene, NOWDiagnostics, nRichDX, Nucleix, Numares, NuProbe, NX Prenatal, Ohio State University, Oklahoma Medical Research Foundation, Oligomerix, Olink Proteomics, OmiCure, Oncimmune, OncoCyte, OncoDNA, OncoGenesis, OncoHost, OncoNano Medicine, Oncovet, One Lambda, Ono Pharmaceutical, Ontario Institute for Cancer Research, Ontera, Opentrons Labworks, OpGen, OPKO Health, Opto-Systems, OraSure Technologies, Oregon Health Sciences University, OrigiMed, Orpheus Medical, Ortho-Clinical Diagnostics, Oslo University Hospital, OvuSense, Owlstone Medical, Oxford Nanopore Technologies, Pacific Biosciences, Paige, Pain Therapeutics, Paradigm, Parent Project Muscular Dystrophy, Parexel, Parkway Clinical Laboratories, Passage Bio, Patia, PAVmed, Pennsylvania State University, PeptiDream, PerkinElmer, Personal Genome Diagnostics, Personalis, Perspectum Diagnostics, Pfizer, Pfizer Canada, Pharmacological research Institute Mario Negri, Phase Genomics, Phenomix, Philips, Phillips-Medisize, Phoenix Molecular Designs, PierianDx, Pillar Biosciences, Planet Innovation, Plexision, Point32Health, PPD, Precipio Diagnostics, Precision Diabetes, Precision for Medicine, Precision Pathology Services, PredictImmune, Predictive Technology Group, PrediLife, Premier Inc, Prenetics, Prenosis, Preora Diagnostics, Prescient Medical, Prevencio, Previse, Princeton BioMeditech, Progentec Diagnostics, ProMIS Neurosciences, Prophase Labs, Protea Biosciences, Protean BioDiagnostics, Proteic Bioscience, ProteoMediX, ProterixBio, Provista Diagnostics, Psyche Systems, PTC Therapeutics, PT Elion Medika, Puerto Rico Government, Puma Biotechnology, Q2 Solutions, Qiagen, Quansys Biosciences, Quanterix, QuantumDx, Quantum Leap Health Care Collaborative, Quebec Heart and Lung Institute, Queensland University of Technology, Quest Diagnostics, Qura Therapeutics, Qure Healthcare, Radboud University Nijmegen Medical Centre, Rady Children's Institute for Genomic Medicine, Ragon Institute, Rarecells, Realm IDx, Renegade Bio, Renji Hospital, Repertoire Genesis, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Resolution Bioscience, Reveal Genomics, Rice University, Righton, RNA Disease Diagnostics, Roche, Roche Diagnostics, Rokline Health Concepts, Roswell Biotechnologies, Roswell Park Cancer Institute, Royal Marsden Hospital, Royal Philips Electronics, RTI International, SAGA Diagnostics, Sanofi, Sansure Biotech, Saol Therapeutics, Saphetor, Sapphiros, Sarah Cannon Research Institute, Sarepta Therapeutics, Satio, Scipher Medicine, SC Liver Research Consortium (SCLRC), Seaspring, Seattle Children's Hospital, Sebela Pharmaceuticals, Secarna Pharmaceuticals, Seegene, SeekIn, Sekris Biomedical, Selexis, Sema4, SEngine Precision Medicine, Sentinel Diagnostics, SenzaGen, Sepset Biosciences, Seracare Life Sciences, Sherlock Biosciences, Shire Human Genetic Therapies, Siemens Healthcare, Siemens Healthineers, Simsen Diagnostics, Singlera Genomics, Singulex, Siolta Therapeutics, Skane University Hospital, SkylineDX, Skysong Innovations, Soma BioScience, SomaLogic, Sona Nanotech, Sonic Healthcare, SOPHiA Genetics, Source Molecular, Spectrum Solutions, SpeeDx, Spesana, Sphingotec, SQI Diagnostics, SRI International, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Streck Laboratories, Sumaya Biotech, Sunnybrook Research Institute, Susan G. Komen for the Cure, Swift Biosciences, Swiss Institute of Bioinformatics (SIB), Synexa Life Sciences, Sysmex, Sysmex Inostics, Systec, T-Cure Bioscience, T2 Biosystems, TaiRx, Takara Bio USA, Take2, Takeda Pharmaceutical, Taysha Gene Therapies, Tecan, Tempus, Tesis Biosciences, Texas A&M University, The Binding Site, The Parker Institute For Cancer Immunotherapy, Theralink Technologies, Therma Bright, Thermo Fisher Scientific, ThinkCyte, Thomas Jefferson University, TME Research, Todos Medical, Tokai University, Tolo Biotech, Toronto Innovation Acceleration Partners, Tor Vergata University Hospital, Toyohashi University of Technology, Transcriptome Sciences, Transgenomic, Transplant Genomics, Travera, TrovaGene, True Diagnostics, TScan Therapeutics, TTP Group, Turgut Ilaclari, Twist Bioscience, Tymora Analytical Operations, uBiome, UgenTec, UK Government, UK NEQAS, Uman Diagnostics, UniQuest, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University Hospital Bispebjerg, University Medical Center Hamburg-Eppendorf, University of Antwerp, University of Barcelona, University of Birmingham, University of Bonn, University of Bristol, University of California, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Greifswald, University of Houston, University of Leeds, University of Leuven, University of Manchester, University of Maryland, Baltimore County, University of Maryland Baltimore, University of Melbourne, University of Miami, University of Michigan, University of Minnesota, University of North Carolina, University of Oxford, University of Pennsylvania, University of Rostock, University of Southampton, University of Texas Medical Branch, University of Texas Southwestern Medical Center, University of Tubingen, University of Washington, UPMC, Urology Centers of Alabama, Urology San Antonio, USC Norris Comprehensive Cancer Center, US Department of Commerce, US Government, US Oncology, Vanderbilt University, Varian Medical Systems, Vela Diagnostics, Velsera, Ventana Medical Systems, Veracyte, Veravas, Veritas, Verogen, Versea Ophthalmics, Viatar CTC Solutions, VIB, Victoria University, ViennaLab Diagnostics, Vincere Cancer Center, ViraCor Laboratories, Viravaxx, Vir Biotechnology, VolitionRX, Waseda University, Watchmaker Genomics, Weihai Weigao Medical Devices, Weill Cornell Medical College, Wellcome Trust, WellDyne, Whitman-Walker Institute, Wyss Institute, X4 Pharmaceuticals, XCR Diagnostics, Yale University, Yemaachi Biotech, Yesse Technologies, Yitu Medical, Zenyaku Kogyo, Zomedica, zPREDICTA, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.